266 related articles for article (PubMed ID: 22449547)
21. Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10.
Ishikura N; Kawata H; Nishimoto A; Nakamura R; Ishii N; Aoki Y
Prostate; 2010 Apr; 70(5):457-66. PubMed ID: 19902465
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis and biological evaluation of novel 5-oxo-2-thioxoimidazolidine derivatives as potent androgen receptor antagonists.
Ivachtchenko AV; Ivanenkov YA; Mitkin OD; Vorobiev AA; Kuznetsova IV; Shevkun NA; Koryakova AG; Karapetian RN; Trifelenkov AS; Kravchenko DV; Veselov MS; Chufarova NV
Eur J Med Chem; 2015 Jun; 99():51-66. PubMed ID: 26046313
[TBL] [Abstract][Full Text] [Related]
23. Regulation of prostate-specific antigen by activin A in prostate cancer LNCaP cells.
Fujii Y; Kawakami S; Okada Y; Kageyama Y; Kihara K
Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E927-31. PubMed ID: 14761877
[TBL] [Abstract][Full Text] [Related]
24. Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters.
Simard J; Singh SM; Labrie F
Urology; 1997 Apr; 49(4):580-6; discussion 586-9. PubMed ID: 9111629
[TBL] [Abstract][Full Text] [Related]
25. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
[TBL] [Abstract][Full Text] [Related]
26. A selective androgen receptor modulator that reduces prostate tumor size and prevents orchidectomy-induced bone loss in rats.
Allan G; Lai MT; Sbriscia T; Linton O; Haynes-Johnson D; Bhattacharjee S; Dodds R; Fiordeliso J; Lanter J; Sui Z; Lundeen S
J Steroid Biochem Mol Biol; 2007 Jan; 103(1):76-83. PubMed ID: 17049844
[TBL] [Abstract][Full Text] [Related]
27. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
Quéro L; Giocanti N; Hennequin C; Favaudon V
Prostate; 2010 Mar; 70(4):401-11. PubMed ID: 19902473
[TBL] [Abstract][Full Text] [Related]
28. Development of androgen- and estrogen-responsive bioassays, members of a panel of human cell line-based highly selective steroid-responsive bioassays.
Sonneveld E; Jansen HJ; Riteco JA; Brouwer A; van der Burg B
Toxicol Sci; 2005 Jan; 83(1):136-48. PubMed ID: 15483189
[TBL] [Abstract][Full Text] [Related]
29. Development of two androgen receptor assays using adenoviral transduction of MMTV-luc reporter and/or hAR for endocrine screening.
Hartig PC; Bobseine KL; Britt BH; Cardon MC; Lambright CR; Wilson VS; Gray LE
Toxicol Sci; 2002 Mar; 66(1):82-90. PubMed ID: 11861975
[TBL] [Abstract][Full Text] [Related]
30. Receptor affinity and potency of non-steroidal antiandrogens: translation of preclinical findings into clinical activity.
Kolvenbag GJ; Furr BJ; Blackledge GR
Prostate Cancer Prostatic Dis; 1998 Dec; 1(6):307-314. PubMed ID: 12496872
[TBL] [Abstract][Full Text] [Related]
31. A novel synthetic androgen receptor ligand, S42, works as a selective androgen receptor modulator and possesses metabolic effects with little impact on the prostate.
Min L; Yanase T; Tanaka T; Fan W; Nomura M; Kawate H; Okabe T; Takayanagi R; Nawata H
Endocrinology; 2009 Dec; 150(12):5606-16. PubMed ID: 19854864
[TBL] [Abstract][Full Text] [Related]
32. Effect of small molecules modulating androgen receptor (SARMs) in human prostate cancer models.
Tesei A; Leonetti C; Di Donato M; Gabucci E; Porru M; Varchi G; Guerrini A; Amadori D; Arienti C; Pignatta S; Paganelli G; Caraglia M; Castoria G; Zoli W
PLoS One; 2013; 8(5):e62657. PubMed ID: 23667504
[TBL] [Abstract][Full Text] [Related]
33. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
34. Mechanism of action of bolandiol (19-nortestosterone-3beta,17beta-diol), a unique anabolic steroid with androgenic, estrogenic, and progestational activities.
Attardi BJ; Page ST; Hild SA; Coss CC; Matsumoto AM
J Steroid Biochem Mol Biol; 2010 Feb; 118(3):151-61. PubMed ID: 19941958
[TBL] [Abstract][Full Text] [Related]
35. Antiandrogenic and growth inhibitory effects of ring-substituted analogs of 3,3'-diindolylmethane (ring-DIMs) in hormone-responsive LNCaP human prostate cancer cells.
Abdelbaqi K; Lack N; Guns ET; Kotha L; Safe S; Sanderson JT
Prostate; 2011 Sep; 71(13):1401-12. PubMed ID: 21321979
[TBL] [Abstract][Full Text] [Related]
36. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
[TBL] [Abstract][Full Text] [Related]
37. Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms.
Jia L; Kim J; Shen H; Clark PE; Tilley WD; Coetzee GA
Mol Cancer Res; 2003 Mar; 1(5):385-92. PubMed ID: 12651911
[TBL] [Abstract][Full Text] [Related]
38. Androgen receptor antagonists (antiandrogens): structure-activity relationships.
Singh SM; Gauthier S; Labrie F
Curr Med Chem; 2000 Feb; 7(2):211-47. PubMed ID: 10637363
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists.
Yamamoto S; Kobayashi H; Kaku T; Aikawa K; Hara T; Yamaoka M; Kanzaki N; Hasuoka A; Baba A; Ito M
Bioorg Med Chem; 2013 Jan; 21(1):70-83. PubMed ID: 23199477
[TBL] [Abstract][Full Text] [Related]
40. Dehydroepiandrosterone-induced proliferation of prostatic epithelial cell is mediated by NFKB via PI3K/AKT signaling pathway.
Sun HZ; Yang TW; Zang WJ; Wu SF
J Endocrinol; 2010 Mar; 204(3):311-8. PubMed ID: 20007738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
